CENTO, VALERIA
CENTO, VALERIA
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district
2016-09-01 Polilli, E; Cento, V; Restelli, U; CECCHERINI SILBERSTEIN, F; Aragri, M; DI MAIO, Vc; Sciacca, A; Santoleri, F; Fazii, P; Costantini, A; Perno, Cf; Parruti, G
Detecting hepatitis B viral amino acid sequence mutations in occult hepatitis B infections via bayesian partition model
2013-01-01 Lian, Z; Tian, Qn; Liu, Y; Cento, V; Salpini, R; Perno, Cf; Svicher, V; Chen, G; Li, C; Zhang, J
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning
2017-05-09 Cuypers, L; Libin, P; Schrooten, Y; Theys, K; DI MAIO, Vc; Cento, V; Lunar, M; Nevens, F; Poljak, M; CECCHERINI SILBERSTEIN, F; Nowé, A; Van Laethem, K; Vandamme, A
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay
2017-04-11 Antonucci, F; Cento, V; Sorbo, M; Manuelli, M; Lenci, I; Sforza, D; Di Carlo, D; Milana, M; Manzia, Tm; Angelico, M; Tisone, G; Perno, Cf; CECCHERINI SILBERSTEIN, F
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors
2014-05-01 Di Maio, V; Cento, V; Mirabelli, C; Artese, A; Costa, G; Alcaro, S; Perno, Cf; CECCHERINI SILBERSTEIN, F
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome
2015-02-01 Cento, V; Di Paolo, D; Di Carlo, D; Micheli, V; Tontodonati, M; De Leonardis, F; Aragri, M; Antonucci, F; Di Maio, V; Mancon, A; Lenci, I; Manunta, A; Taliani, G; Di Biagio, A; Nicolini, L; Nosotti, L; Sarrecchia, C; Siciliano, M; Landonio, S; Pellicelli, A; Gasbarrini, A; Vecchiet, J; Magni, C; Babudieri, S; Mura, M; Andreoni, M; Parruti, G; Rizzardini, G; Angelico, M; Perno, Cf; CECCHERINI SILBERSTEIN, F
Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
2017-01-01 Cuypers, L; Vrancken, B; Fabeni, L; Marascio, N; Cento, V; DI MAIO, Vc; Aragri, M; Pineda Pena, A; Schrooten, Y; Van Laethem, K; Balog, D; Foca, A; Torti, C; Nevens, F; Perno, Cf; Vandamme, A; CECCHERINI SILBERSTEIN, F
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens
2017-01-01 Cento, V; Nguyen, T; Di Carlo, D; Biliotti, E; Gianserra, L; Lenci, I; DI PAOLO, D; Calvaruso, V; Teti, E; Cerrone, M; Romagnoli, D; Melis, M; Danieli, E; Menzaghi, B; Polilli, E; Siciliano, M; Nicolini, L; Di Biagio, A; Magni, C; Bolis, M; Antonucci, F; DI MAIO, Vc; Alfieri, R; Sarmati, L; Casalino, P; Bernardini, S; Micheli, V; Rizzardini, G; Parruti, G; Quirino, T; Puoti, M; Babudieri, S; D'Arminio Monforte, A; Andreoni, M; Craxì, A; Angelico, M; Pasquazzi, C; Taliani, G; Guedj, J; Perno, Cf; CECCHERINI SILBERSTEIN, F
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study
2017-09-18 Cento, V; Aragri, M; Teti, E; Polilli, E; Bertoli, A; Foroghi, L; Barbaliscia, S; DI MAIO, Vc; Pieri, A; Pace Palitti, V; Sarmati, L; Parruti, G; Andreoni, M; Perno, Cf; CECCHERINI SILBERSTEIN, F
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life.
2017-01-01 Cento, V; Barbaliscia, S; Lenci, I; Ruggiero, T; Magni, C; Paolucci, S; Babudieri, S; Siciliano, M; Pasquazzi, C; Ciancio, A; Perno, Cf; CECCHERINI SILBERSTEIN, F; Micheli, V; Troshina, Y; Biliotti, E; Milana, M; Melis, M; Teti, E; Lambiase, L; Menzaghi, B; Nicolini, L; Marenco, S; DI MAIO, Vc; Aragri, M; Pecchioli, A; Bertoli, A; Sarrecchia, C; Macera, M; Coppola, N; Puoti, M; Romagnoli, D; Pellicelli, A; Bonora, S; Novati, S; Baldanti, F; Ghisetti, V; Andreoni, M; Taliani, G; Rizzardini, G; Angelico, M
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals
2023-11-01 Armenia, D; Gagliardini, R; Alteri, C; Svicher, V; Cento, V; Borghi, V; Vergori, A; Cicalini, S; Forbici, F; Fabeni, L; Bertoli, A; Brugneti, M; Gennari, W; Malagnino, V; Andreoni, M; Mussini, C; Antinori, A; Perno, Cf; Santoro, Mm; Ceccherini-Silberstein, F
| Data di pubblicazione | Titolo | Autore(i) | Tipo | File |
|---|---|---|---|---|
| 1-set-2016 | Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district | Polilli, E; Cento, V; Restelli, U; CECCHERINI SILBERSTEIN, F; Aragri, M; DI MAIO, Vc; Sciacca, A; Santoleri, F; Fazii, P; Costantini, A; Perno, Cf; Parruti, G | Articolo su rivista | |
| 1-gen-2013 | Detecting hepatitis B viral amino acid sequence mutations in occult hepatitis B infections via bayesian partition model | Lian, Z; Tian, Qn; Liu, Y; Cento, V; Salpini, R; Perno, Cf; Svicher, V; Chen, G; Li, C; Zhang, J | Articolo su rivista | |
| 9-mag-2017 | Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning | Cuypers, L; Libin, P; Schrooten, Y; Theys, K; DI MAIO, Vc; Cento, V; Lunar, M; Nevens, F; Poljak, M; CECCHERINI SILBERSTEIN, F; Nowé, A; Van Laethem, K; Vandamme, A | Articolo su rivista | |
| 11-apr-2017 | HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay | Antonucci, F; Cento, V; Sorbo, M; Manuelli, M; Lenci, I; Sforza, D; Di Carlo, D; Milana, M; Manzia, Tm; Angelico, M; Tisone, G; Perno, Cf; CECCHERINI SILBERSTEIN, F | Articolo su rivista | |
| 1-mag-2014 | Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors | Di Maio, V; Cento, V; Mirabelli, C; Artese, A; Costa, G; Alcaro, S; Perno, Cf; CECCHERINI SILBERSTEIN, F | Articolo su rivista | |
| 1-feb-2015 | Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome | Cento, V; Di Paolo, D; Di Carlo, D; Micheli, V; Tontodonati, M; De Leonardis, F; Aragri, M; Antonucci, F; Di Maio, V; Mancon, A; Lenci, I; Manunta, A; Taliani, G; Di Biagio, A; Nicolini, L; Nosotti, L; Sarrecchia, C; Siciliano, M; Landonio, S; Pellicelli, A; Gasbarrini, A; Vecchiet, J; Magni, C; Babudieri, S; Mura, M; Andreoni, M; Parruti, G; Rizzardini, G; Angelico, M; Perno, Cf; CECCHERINI SILBERSTEIN, F | Articolo su rivista | |
| 1-gen-2017 | Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy | Cuypers, L; Vrancken, B; Fabeni, L; Marascio, N; Cento, V; DI MAIO, Vc; Aragri, M; Pineda Pena, A; Schrooten, Y; Van Laethem, K; Balog, D; Foca, A; Torti, C; Nevens, F; Perno, Cf; Vandamme, A; CECCHERINI SILBERSTEIN, F | Articolo su rivista | |
| 1-gen-2017 | Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens | Cento, V; Nguyen, T; Di Carlo, D; Biliotti, E; Gianserra, L; Lenci, I; DI PAOLO, D; Calvaruso, V; Teti, E; Cerrone, M; Romagnoli, D; Melis, M; Danieli, E; Menzaghi, B; Polilli, E; Siciliano, M; Nicolini, L; Di Biagio, A; Magni, C; Bolis, M; Antonucci, F; DI MAIO, Vc; Alfieri, R; Sarmati, L; Casalino, P; Bernardini, S; Micheli, V; Rizzardini, G; Parruti, G; Quirino, T; Puoti, M; Babudieri, S; D'Arminio Monforte, A; Andreoni, M; Craxì, A; Angelico, M; Pasquazzi, C; Taliani, G; Guedj, J; Perno, Cf; CECCHERINI SILBERSTEIN, F | Articolo su rivista | |
| 18-set-2017 | Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study | Cento, V; Aragri, M; Teti, E; Polilli, E; Bertoli, A; Foroghi, L; Barbaliscia, S; DI MAIO, Vc; Pieri, A; Pace Palitti, V; Sarmati, L; Parruti, G; Andreoni, M; Perno, Cf; CECCHERINI SILBERSTEIN, F | Articolo su rivista | |
| 1-gen-2017 | Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. | Cento, V; Barbaliscia, S; Lenci, I; Ruggiero, T; Magni, C; Paolucci, S; Babudieri, S; Siciliano, M; Pasquazzi, C; Ciancio, A; Perno, Cf; CECCHERINI SILBERSTEIN, F; Micheli, V; Troshina, Y; Biliotti, E; Milana, M; Melis, M; Teti, E; Lambiase, L; Menzaghi, B; Nicolini, L; Marenco, S; DI MAIO, Vc; Aragri, M; Pecchioli, A; Bertoli, A; Sarrecchia, C; Macera, M; Coppola, N; Puoti, M; Romagnoli, D; Pellicelli, A; Bonora, S; Novati, S; Baldanti, F; Ghisetti, V; Andreoni, M; Taliani, G; Rizzardini, G; Angelico, M | Articolo su rivista | |
| 1-nov-2023 | Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals | Armenia, D; Gagliardini, R; Alteri, C; Svicher, V; Cento, V; Borghi, V; Vergori, A; Cicalini, S; Forbici, F; Fabeni, L; Bertoli, A; Brugneti, M; Gennari, W; Malagnino, V; Andreoni, M; Mussini, C; Antinori, A; Perno, Cf; Santoro, Mm; Ceccherini-Silberstein, F | Articolo su rivista |